Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
105 hedge funds and large institutions have $238M invested in Paratek Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 28 reducing their positions, and 18 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less funds holding
Funds holding: 110 → 105 (-5)
7% less capital invested
Capital invested by funds: $255M → $238M (-$17.7M)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
67% less call options, than puts
Call options by funds: $290K | Put options by funds: $874K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$7.43M |
| 2 |
APCM
Arbiter Partners Capital Management
New York
|
+$2.18M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.93M |
| 4 |
Two Sigma Investments
New York
|
+$1.57M |
| 5 |
WIC
Water Island Capital
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.93M |
| 2 |
Renaissance Technologies
New York
|
-$3.26M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.98M |
| 4 |
Man Group
London,
United Kingdom
|
-$2.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.29M |
PRTK Hedge Fund Activity: Q3 2018 in Review
105 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2018, worth a combined $238M — down 6.9% from $255M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PRTK and 13 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 36 added.
The largest buyer was Highland Capital Management (Texas), adding an estimated $7.43M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $4.93M sold.
- 105 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2018, down from 110 in Q2 2018.
- Funds reported $238M of Paratek Pharmaceuticals, Inc. stock for Q3 2018, down 6.9% quarter-over-quarter.
- 13 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2018 and 18 closed out, a net change of -5 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2018 was Highland Capital Management (Texas), an estimated $7.43M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2018 was Alyeska Investment Group, an estimated $4.93M sold.
Based on aggregated 13F filings for Q3 2018.